🟢 Outlook Therapeutics is trading 5.3% up today on executive bonuses tied to FDA approval of ONS-5010

Outlook Therapeutics is trading 5.3% up today at $1.39 after the company approved new executive stock option grants and performance-based cash bonuses tied specifically to FDA approval of its lead drug candidate ONS-5010.

• The compensation move highlights growing investor focus on the upcoming FDA decision window for ONS-5010 (LYTENAVA) in wet age-related macular degeneration.
• The incentive structure is helping maintain speculative interest ahead of the key regulatory catalyst for the company's lead asset.